Caroline Palomeque
Stock Analyst at Maxim Group
(2.59)
# 2,112
Out of 4,854 analysts
9
Total ratings
55.56%
Success rate
16.24%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Caroline Palomeque
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DARE Daré Bioscience | Downgrades: Hold | n/a | $3.23 | - | 2 | Aug 14, 2024 | |
| HRMY Harmony Biosciences Holdings | Initiates: Buy | $59 | $35.45 | +66.46% | 1 | Sep 7, 2023 | |
| KRYS Krystal Biotech | Initiates: Buy | $154 | $135.40 | +13.74% | 1 | Sep 7, 2023 | |
| HALO Halozyme Therapeutics | Reinstates: Buy | $58 | $54.09 | +7.24% | 1 | Mar 27, 2023 | |
| ASND Ascendis Pharma | Assumes: Buy | $166 | $174.02 | -4.61% | 1 | Aug 30, 2022 | |
| DNLI Denali Therapeutics | Initiates: Buy | $39 | $15.00 | +160.09% | 1 | Jun 23, 2022 | |
| RGNX REGENXBIO | Initiates: Buy | $61 | $9.68 | +530.17% | 1 | Jun 23, 2022 | |
| AVXL Anavex Life Sciences | Initiates: Buy | $40 | $8.04 | +397.82% | 1 | Jun 23, 2022 |
Daré Bioscience
Aug 14, 2024
Downgrades: Hold
Price Target: n/a
Current: $3.23
Upside: -
Harmony Biosciences Holdings
Sep 7, 2023
Initiates: Buy
Price Target: $59
Current: $35.45
Upside: +66.46%
Krystal Biotech
Sep 7, 2023
Initiates: Buy
Price Target: $154
Current: $135.40
Upside: +13.74%
Halozyme Therapeutics
Mar 27, 2023
Reinstates: Buy
Price Target: $58
Current: $54.09
Upside: +7.24%
Ascendis Pharma
Aug 30, 2022
Assumes: Buy
Price Target: $166
Current: $174.02
Upside: -4.61%
Denali Therapeutics
Jun 23, 2022
Initiates: Buy
Price Target: $39
Current: $15.00
Upside: +160.09%
REGENXBIO
Jun 23, 2022
Initiates: Buy
Price Target: $61
Current: $9.68
Upside: +530.17%
Anavex Life Sciences
Jun 23, 2022
Initiates: Buy
Price Target: $40
Current: $8.04
Upside: +397.82%